In Brief - Glythera and Iontas in licensing deal for ADCs

UK biotechs Glythera and Iontas have announced a collaboration for the development of antibody drug conjugates (ADCs) for difficult-to-treat cancers.

As part of the agreement, Iontas will generate novel, fully human antibodies against specified targets for proof-of-concept studies. Glythera will have an option for exclusive, worldwide rights to resulting antibodies for the development of ADCs alongside its proprietary conjugation platform, PermaLink and its in-house portfolio of novel toxins. Iontas will receive undisclosed development and clinical milestone payments on each of the ADCs.